Voxelotor Brain Oxygenation and Neurocognitive Study

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 9, 2023

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions
Sickle Cell Disease
Interventions
DRUG

Voxelotor Oral Tablet

During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment

Trial Locations (2)

10467

The Children's Hospital at Montefiore, The Bronx

63110

Washington University School of Medicine, St Louis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY